- Home
- GRVY vs MREO Comparison
GRVY vs MREO Comparison
Compare GRVY & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRVY | MREO |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | South Korea | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.1M | 324.6M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | GRVY | MREO |
|---|---|---|
| Price | $68.91 | $0.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 29.6K | ★ 6.8M |
| Earning Date | 11-07-2025 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.02 | N/A |
| Revenue | ★ $399,496,744.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,363.05 |
| P/E Ratio | $8.30 | ★ N/A |
| Revenue Growth | ★ 12.13 | N/A |
| 52 Week Low | $53.12 | $0.20 |
| 52 Week High | $74.75 | $3.05 |
Technical Indicators
Market Signals| Indicator | GRVY | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 32.09 |
| Support Level | $68.00 | $0.36 |
| Resistance Level | $70.01 | $0.44 |
| Average True Range (ATR) | 3.80 | 0.05 |
| MACD | -0.70 | 0.04 |
| Stochastic Oscillator | 25.53 | 17.68 |
Price Performance
Historical ComparisonAbout GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. Its principal product, Ragnarok Online, is an online game which is available in more than 91 markets. Its games include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).